【摘要】 目的:探讨来那度胺联合硼替佐米治疗多发性骨髓瘤的疗效及血清IL-2、免疫功能的影响。方法:将在我院确诊并接受治疗的80例多发性骨髓瘤患者,随机分为两组,40例对照组采用硼替佐米联合地塞米松治疗,40例观察组在对照组基础上联合来那度胺进行治疗,连续治疗2个月后,比较两组治疗前后的M蛋白、β₂微球蛋白、白介素-2（IL-2）、免疫功能以及疗效。结果:观察组治疗后的M蛋白和β₂微球蛋白均低于对照组,而且IL-2含量高于对照组（P<0.05）;观察组治疗后的CD3⁺、CD4⁺和CD4⁺/CD8⁺均高于对照组,差异具有统计学意义（P<0.05）;观察组总有效率为87.5%,明显高于对照组的62.5%,差异具有统计学意义（P<0.05）。结论:来那度胺联合硼替佐米能有效地改善多发性骨髓瘤患者的免疫能力,降低炎症反应的发生,进一步促进患者的康复,具有重要意义。更多还原

【Abstract】 Objective: To investigate the efficacy of lenalidomide combined with bortezomib in the treatment of multiple myeloma and its effects on serum IL-2 and the immune functions. Methods: 80 patients with multiple myeloma diagnosed and treated in our hospital were randomized into two groups, 40 patients in the control group were treated with bortezomib plus dexamethasone, while another 40 in the observation groups were treated with lenalidomide on the basis of the control group. After 2 months of continuous treatment, Mprotein, β₂ microglobulin, interleukin-2（IL-2）, immune function and efficacy of both groups were compared before and after treatment. Results: M protein and β₂ microglobulin in the observation group were lower than those of the control group, while IL-2 level was higher than that of the control group（P<0.05）. CD3⁺, CD4⁺ and CD4⁺/CD8⁺ levels in the observation group were higher than those of the control group（P<0.05）; the total effective rate of the observation group was 87.5%, significantly higher than that of the control group（62.5%）（P<0.05）. Conclusion: Lenalidomide combined with bortezomib can effectively improve the immune ability of patients with multiple myeloma, reduce the occurrence of inflammatory reaction, and further promote the recovery of patients, which is of great significance.更多还原